An Open-label, Phase 1 Study of the Relative Bioavailability, Food Effect, Safety and Tolerability of an Oral Solution Formulation of MLN8237 in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2015
At a glance
- Drugs Alisertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Millennium
- 12 Dec 2015 Pharmacokinetic results of this study (n=24) published in the Drugs in R and D.
- 18 Jun 2012 Actual patient number (53) added as reported by ClinicalTrials.gov.
- 18 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.